Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024 Company to host a live webcast and conference call today at 7:15 PM ET / 6:15 PM CT (OXFORDSHIRE, England & CONSHOHOCKEN, PA & ROCKVILLE, MD, US, 31 May 2024) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating med ...

Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma Following recent consultation with FDA, all patients randomized from start of TEBE-AM Phase 2/3 trial will be included in the Phase 3 intent-to-treat population Phase 3 will continue three arms: KIMMTRAK monotherapy, KIMMTRAK in combination with pembrolizumab, and control Expected to accelerate time to final Phase 3 overall survival analysis (OXFORDSHI ...

Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma Following recent consultation with FDA, all patients randomized from start of TEBE-AM Phase 2/3 trial will be included in the Phase 3 intent-to-treat population Phase 3 will continue three arms: KIMMTRAK monotherapy, KIMMTRAK in combination with pembrolizumab, and control Expected to accelerate time to final Phase 3 overall survival analysis (OXFORDSHI ...

Exhibit 99.1 Immunocore reports first quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $70.3 million in Q1 2024; continuing to expand global access with 7 additional launches since January 2024 Phase 1/2 brenetafusp (IMC-F106C; PRAME-A02) clinical data in post-checkpoint late-line cutaneous melanoma selected for oral presentation at ASCO 2024 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, May 8, 2024) Immunocore Holdings plc (Nasdaq: IM ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Commission File Number: 001-39992 Immunocore Holdings plc (Exact name of registrant as specified in its charter) | England and Wales | Not Applicable | | --- | --- | | (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) | | 92 Park Drive Milton Park | | | Abingdon, Oxfordshire, United Kingdom | OX14 4RY | | (Address of principal executive offices) | (Zip Code) | | +44 1235 4386 ...

Immunocore Holdings plc (NASDAQ:IMCR) Q4 2023 Earnings Conference Call February 28, 2024 8:00 AM ET Company Participants Clayton Robertson - Head, IR Bahija Jallal - CEO Ralph Torbay - Head, Commercial David Berman - Head, R&D Brian Di Donato - CFO Mohammed Dar - CMO Conference Call Participants Michael Yee - Jefferies Jessica Fye - JP Morgan Tyler Van Buren - TD Cowen Eric Schmidt - Cantor Fitzgerald Paul Jeng - Guggenheim Avantika Joshi - Mizuho Peter Lawson - Barclays Charlie Moore - Baird Jeet Mukherjee ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the period from ________ to ________ Commission File Number 001-39992 Immunocore Holdings plc (Exact name of registrant as specified in its charter) England and Wales Not Applicable (State o ...

Unaudited Condensed Consolidated Statements of Profit / (Loss) and Comprehensive (Loss) / Income Exhibit 99.1 Immunocore Holdings plc Unaudited Condensed Consolidated Interim Financial Statements | | | Three Months Ended | | Nine Months Ended | | | --- | --- | --- | --- | --- | --- | | | | September 30, | | September 30, | | | | | 2023 | 2022 | 2023 | 2022 | | | Notes | £'000 | £'000 | £'000 | £'000 | | Product revenue, net | 3 | 49,719 | 33,252 | 137,285 | 64,926 | | Pre-product revenue, net | 3 | — | 3,05 ...

Immunocore Holdings plc (NASDAQ:IMCR) Q2 2023 Earnings Conference Call August 10, 2023 8:00 AM ET Company Participants Clayton Robertson - Head of IR Bahija Jallal - CEO and Director Brian Di Donato - CFO and Head of Strategy Ralph Torbay - Head of Commercial David Berman - Head of R&D Mohammed Dar - CMO Conference Call Participants Michael Yee - Jefferies Tyler Van Buren - TD Cowen Justin Zelin - BTIG Graig Suvannavejh - Mizuho Justin Kim - Oppenheimer Michael Schmidt - Guggenheim Patrick Trucchio - H.C. W ...

Exhibit 99.1 Immunocore Holdings plc Unaudited Condensed Consolidated Interim Financial Statements | | Notes | £'000 | £'000 | £'000 | £'000 | £'000 | £'000 | £'000 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | At January 1, 2022 | | 88 | 212,238 | 89 | 54,357 | 386,167 | (481,392) | 171,547 | | Loss for the period | | — | — | — | — | — | (16,128) | (16,128) | | Other comprehensive | | | | | | | | | | income | | — | — | 205 | — | — | — | 205 | | Total comprehensive | | | | | | | | | | loss for ...